Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call: Revenue Up 99%, Guidance Raised
Source Tradingkey
Key Takeaways
- Q2 2026 revenue increased 99% year over year to a record $37.6 million, led by the Hemangiol relaunch and growth across Increlex, the adrenal franchise, Galzin and carglumic acid.
- Adjusted EBITDA rose to $16.2 million, or 43% of revenue, from $3.1 million, or 16% of revenue, in Q2 2025. GAAP net income reached $11.6 million, or $0.35 per diluted share.
- Management raised full-year 2026 revenue guidance to more than $145 million from more than $120 million. Expected adjusted EBITDA margin increased to above 35% from above 30%.
- Hemangiol became Eton’s largest product following its May 1 relaunch. Approximately 95% of patients had transitioned to Eton Cares by the end of June, and management said the transition is now complete.
- Eton licensed ASN001, a late-stage topical treatment candidate for infantile hemangiomas. The company plans a 24-patient bioavailability study and expects to submit an NDA in the second half of 2027, potentially supporting a 2028 launch.
- Eton ended the quarter with $26.8 million in cash after a $3 million debt prepayment. The company plans to prioritize accretive product acquisitions while accelerating repayment of its remaining credit facility over the next six to 12 months.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | $37.6 million | $18.9 million | Up 99% year over year |
| Gross profit | $25.4 million | $11.9 million | Up 113% |
| Adjusted gross profit | $27.4 million | $14.1 million | Adjusted margin was 73% versus 75% |
| R&D expense | $1.0 million | $3.7 million | Prior-year period included a Desmoda FDA filing fee |
| G&A expense | $11.6 million | $9.7 million | Up 20% |
| Adjusted EBITDA | $16.2 million | $3.1 million | Margin expanded to 43% from 16% |
| GAAP net income | $11.6 million | $(2.6) million | Diluted EPS of $0.35 versus a loss of $0.10 |
| Non-GAAP net income | $14.3 million | $1.5 million | Diluted EPS of $0.43 versus $0.03 |
| Cash at quarter-end | $26.8 million | — | After a $3 million debt prepayment |
Business and Operating Performance
Hemangiol and pediatric dermatology
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Alphabet (GOOGL) stock climbed about 3% on Monday. The trigger was a report from The Information that Google is building a new AI chip, called Frozen v2, to run its Gemini models up to 10 times more e
Nvidia reports Q2 earnings on August 26, and Wall Street already knows the headline number. Analysts expect about $92 billion in revenue and earnings per share of $2.08, double the year-ago figure.The
Reddit shares surged 11% in extended trading Thursday after S&P Dow Jones Indices confirmed the platform will join the S&P 500.Reddit is only the second pureplay social media stock in the benchmark in
Micron (MU) stock is holding near $911 after a 189% price rise in 2026. Yet, Wall Street still sees roughly 70% more upside. And there is good reason behind this optimism. The world is short of the me
SpaceX (SPCX) stock rose 12% on Wednesday to $149.29. That is a 36% gain in five sessions and more than $500 billion in new market value.The trigger was software, not rockets. SpaceXAI, the company’s
